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The angiogenesis process is a key event for glioma survival, malignancy and growth. The start of angiogenesis is mediated by
a cascade of intratumoural events: alteration of the microvasculature network; a hypoxic microenvironment; adaptation of
neoplastic cells and synthesis of pro-angiogenic factors. Due to a chaotic blood flow, a consequence of an aberrant
microvasculature, tissue hypoxia phenomena are induced. Hypoxia inducible factor 1 is a major regulator in glioma invasiveness
and angiogenesis. Clones of neoplastic cells with stem cell characteristics are selected by HIF-1. These cells, called “glioma stem
cells” induce the synthesis of vascular endothelial growth factor. This factor is a pivotal mediator of angiogenesis. To elucidate
the role of these angiogenic mediators during glioma growth, we have used a rat endogenous glioma model. Gliomas induced
by prenatal ENU administration allowed us to study angiogenic events from early to advanced tumour stages. Events such as
microvascular aberrations, hypoxia, GSC selection and VEGF synthesis may be studied in depth. Our data showed that for the
treatment of gliomas, developing anti-angiogenic therapies could be aimed at GSCs, HIF-1 or VEGF. The ENU-glioma model can
be considered to be a useful option to check novel designs of these treatment strategies.
1. Introduction
Gliomas are the most common type of primary tumour in
the central nervous system. Glioblastomas (GBM) are the
malignant form of gliomas (World Health Organization
Grade IV), and progress from a lower-grade glioma (sec-
ondary GBM) or appear de novo without any preceding
tumour (primary GBM). Glioblastomas are strongly angiog-
enic tumours displaying a high degree of vascular prolifer-
ation and endothelial hyperplasia. It is a neoplasia of glial
lineage with high proliferative and invasive capacity and may
spread to occupy an entire lobe or even a hemisphere of the
brain [1].
The growth of the glioblastoma is related to vascular net-
work adaptation due to the increase of the metabolic necessi-
ties of neoplastic cells. During the early stages of gliomas, the
metabolic demand is supplied by the vast microvasculature
of the CNS; however, when the metabolic supply capacity
is exceeded during neoplastic progression, new formation of
vessels becomes necessary [2–4]. The genesis of new vessels
from preexisting ones is called angiogenesis, in opposition to
vasculogenesis, which refers to the formation of vessels from
hematopoietic niches [5, 6].
Angiogenesis is a complex phenomenon, necessary for
the progression of malignant gliomas [7]. The start of the
angiogenesis process requires some angiogenic exogenous
stimulus, such as hypoxia, current metabolic requirements,
and tumour growth. More than 25 diﬀerent growth factors
and cytokines related to the induction of angiogenesis have
been reported [8]. The production of these proangiogenic
factors is a result of genetic alterations or is induced by
hypoxia.
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Intratumour hypoxia occurs at the time when there is an
imbalance between oxygen supply and demand, due to irreg-
ular and chaotic blood flow [9]. This situation triggers the
synthesis of proangiogenic factors such as matrix metallo-
protease (MMP-2), angiopoietin-1, phosphoglycerate kinase
(PGK), erythropoietin (EPO), and vascular endothelial
growth factor (VEGF)-A [10]. Some of these are mediated by
the hypoxia inducible factor (HIF-1). The increase of pro-
angiogenic factors induces the start of angiogenesis, also
known as the “angiogenic switch.” This is a key moment for
tumour malignancy, a critical step for the formation of new
blood vessels and for the adaptation of the microenviron-
ment to the growth of gliomas [11–13].
Vascular endothelial growth factor (VEGF) is the major
regulator of angiogenesis in development [14–16] and dis-
ease [17–19]. VEGF-A triggers the angiogenic switch [4],
reaching the target cells (endothelial cells) that express VEGF
receptors [20]. However, the role of VEGF in nervous tissue
is even more extensive. Previous studies have shown that
VEGF also has strong neuroprotective, neurotrophic and
neurogenic properties [11, 21–23]. The synthesis of VEGF
is mediated by hypoxia inducible factor (HIF-1). Recently,
researchers have reported that some neoplastic cells with
stem cell characteristics called “glioma stem cells” play a
pivotal role, inducing angiogenesis via HIF-1/VEGF [24].
Hypoxia has been related to clone selection of tumour cells.
Clones adapted to the tumour microenvironment have
acquired the phenotype of tumour stem cells, with increased
proliferative and infiltrative capacity [25, 26]. Invasion of
adjacent normal parenchyma has also been attributed to
glioma stem cells.
The onset of angiogenesis is mediated by a cascade of
intratumoural events: alteration of the microvasculature net-
work; a hypoxic microenvironment; adaptation of neoplastic
cells; synthesis of proangiogenic factors,; finally the genera-
tion of new vessels. This chronological sequence of events
is diﬃcult to study during human glioma development.
In order to follow the natural development of glioma
pathogenesis, an endogenous glioma in rats was generated
by transplacental administration of the carcinogen ethylni-
trosourea (ENU) [27–30]. It has been reported that ENU
gliomas are a representative model for human gliomas due
to their location and also to their similar molecular and
genetic alterations [31]. According to our experience, ENU-
gliomas have proven to be a useful tool in the study of
many aspects of tumourigenesis and neoangiogenesis. This
model permits various neoplastic stages to be isolated, to
study the microvascular aberration process, the role of the
proangiogenic cytokine VEGF and the glioma stem cells.
This knowledge will contribute to define modern targets for
anti-tumoural therapies.
2. Vascular Endothelial Growth Factor (VEGF)
Angiogenesis is a complex process that requires proteolytic
and mitogenic activity of endothelial cells and interaction
of these with the extracellular matrix molecules and peri-
endothelial support cells (pericytes and smooth muscle
cells). Numerous molecules and pathways are involved in
this process, such as HIF-1, VEGF-A, its receptors VEGFR-1
and VEGFR-2, the endothelial receptor tyrosine kinase tie-1
and tie-2, and the angiopoietin ligands 1 and 2. Many other
molecules, such as PDGF and TGF-B, integrin receptors, and
so forth play a very important role.
The VEGF family consists of seven diﬀerent homologous
factors, VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E,
VEGF-F, and placental growth factor (PIGF) [32]. VEGF-A
(VEGF) is the predominant form and is a hypoxia-inducible
45KDa homodimeric glycoprotein. It has five different iso-
forms, VEGF123, VEGF145, VEGF165, VEGF189 and VEGF206,
that are produced by alternative splicing. Expression of
VEGF-A was initially detected in a variety of tumour cell
lines, while its receptors VEGFR-1 and VEGFR-2 were pre-
dominantly expressed in endothelial cells [33].
VEGF-A acts as a mitogenic, survival, and antiapoptotic
factor for the endothelial cells from arteries, veins, and lymph
vessels. Faced with increased secretion of VEGF-A and its
binding to receptors on the surface of endothelial cells,
VEGF-A is a signal transducer leading the production of
molecules that include enzymes for the degradation of the
extracellular matrix and for increase vascular permeability.
VEGF-A stimulates endothelial cell (EC) migration, pro-
liferation, survival, permeability and lumen formation.
Dvorak [34] described it as vascular permeability factor
(VPF) due to its ability to induce leakage through the blood
brain barrier (BBB) in some pathological situations [35, 36].
Helmlinger et al. [37] stated that in the vasodilation process,
VEGF induced the elongation of endothelial cells but not
their proliferation. In the angiogenesis process, VEGF works
alongside other factors such as angiopoietin and ephrins
[38].
The synthesis of this proangiogenic cytokine has been
described in neurons, astrocytes, pericytes, smooth muscle
cells, macrophages, lymphoid cells, platelets, and fibroblasts
[39]. In tumours, its synthesis is associated with neoplastic
and endothelial cells of aberrant microvessels [17]. The
VEGF-A gene is hypoxia regulated, due to a binding site
for HIF in the promoter [40]. The rapid proliferation of
the tumour, accompanied by a poor blood flow, leads to a
relatively hypoxic environment in diﬀerent areas of the
tumour [40], resulting in upregulation of VEGF-A.
VEGF-A expression has been profusely reported in sam-
ples obtained from human gliomas [3]. In human glioma bi-
opsies, it has been shown that VEGF-A overexpression corre-
lates directly to proliferation, vascularization, and degree of
malignancy, and therefore corresponds inversely to prognosis
[18, 19, 41]. The material studied from human biopsies
corresponds to advanced stages of tumour development with
an adapted microvascular network. However, little is known
about VEGF-A expression during glioma progression, espe-
cially during the early stages.
3. Hypoxia
During glioma progression, microvessels acquire aberrant
morphologies, becoming tortuous, irregular and dilated,
and displaying vascular leakage [42, 43]. Consequently, the
regional blood flow is irregular and chaotic and the
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functional deficit of blood perfusion induces intratumour
hypoxia and ischemia [43]. Recent evidence suggests that
a vascular collapse may precede angiogenesis in the devel-
opment of the glioma. The vascular collapse leads to the
death of neighbouring tumour cells and the formation
of necrotic areas. In these regions, tissue hypoxia triggers
the expression of HIF-1 and consequently VEGF-A, which
initiates angiogenesis [44, 45].
Hypoxia is a critical aspect of the glioma microenvi-
ronment [46], and it has been associated with poor prog-
nosis, increased angiogenesis, tumour growth, radio-and
chemotherapy resistance, and tumour invasiveness [47, 48].
It was observed that HIF-1 was involved in the oxygen-
dependent expression of many genes, including those for
pro-angiogenic and vascular permeability factors such us:
VEGF [12, 13, 49], endothelial nitric oxide synthase (eNOS),
angiopoietin, ephrin [45, 50], and others such as: glycolytic
enzymes, glucose transporter-1 (Glut-1), transferrin, indu-
cible nitric oxide synthase and heme oxigenase-1 [51], and
TWIST [52]. In addition to oxygen levels, HIF-1 expres-
sion can be aﬀected by several mechanisms, including the
activation of oncogenes such as EGFR or loss of tumour
suppressors, like p53 or PTEN [40].
HIF-1 is a heterodimeric transcriptional factor composed
of two subunits, HIF-1α and HIF-1β. The HIF-1β subunit
is constitutively expressed, whereas the HIF-1α subunit is
regulated by oxygen. The subunit HIF-1α was originally
discovered in 1988 as a unifying factor to the 3′ hypoxia-
inducible gene for erythropoietin (EPO). There are three
isoforms of the alpha subunit: HIF1α, HIF2α (also known as
endothelial PAS-domain protein 1, EPAS1), and HIF3α [53].
HIF1α is responsible for the majority of the hypoxia response
in cancer. Recently, a link has been discovered between HIF-
1α, tumour apoptosis, and the necrosis process [54].
4. Glioma Stem Cells
It has been reported that the hypoxic microenvironment
plays a fundamental role in the induction of the neoplastic
phenotype [55–57]. Some studies elucidated that HIF-2αwas
only significantly present in the cancer stem cells, whereas
HIF-1α was present in both stem and nonstem tumour cells
[56, 57].
Recently, a relationship between HIF-1α, tumour migra-
tion and stem cell biology has been found [47, 58].
Furthermore, studies of human GBM have described the
relationship between the intratumour oxygen gradient and
the appearance of tumour stem cells [59]. These cells,
called “glioma stem cells” (GSCs), are thought to be
responsible for the process of infiltration and subsequent
tumour recurrence. Moreover, it has been reported that the
relationship between angiogenesis and tumour invasiveness
is due to this neoplastic subpopulation. Recently, researchers
have reported that GSCs play a pivotal role in inducing
angiogenesis via HIF-1/VEGF [24, 60].
Due to the regulatory role of GSCs in tumour angio-
genesis, they are currently being considered as a potential
antiangiogenic target. It is a fact that nowadays, research
in novel antitumour therapies has centred on identifying
these neoplastic cells. So far, markers have been used:
CD133/Promonin-1, a prominin family of pentaspan mem-
brane proteins; Nestin, a protein found in neural stem cells
in SVZ and other markers of neuroepithelial stem cells:
Musashi-1, Sox-2, GFAP, Map-2, Neural-tubulin, Neurofila-
ment O4, Noggin, and CD15 have all been proposed in order
to identify tumour stem cells [61–63].
In human glioblastoma, GSCs were identified by CD133
expression and associated with bad prognosis of the tumour
[64, 65]. However, little is known about their genesis during
glioma progression, especially during the early stages.
5. An Experimental Model of
Endogenous Glioma
As has previously been described, the onset of angiogenesis
is mediated by a cascade of intratumoural events, where
both tumour and “non-tumour” cells as well as numerous
cytokines are involved. In order to follow the angiogenesis
process during the neoplasia genesis, we have used an en-
dogenous glioma model. It was generated by transplacental
administration of ethylnitrosourea (ENU) in rats [28, 66,
67].
Previous studies have reported that administration of
ENU to adult rodents did not induce CNS tumours, while
transplacental administration during the perinatal period
(last week of gestation and first week of postnatal time)
induced tumours in more than half of the oﬀspring [68].
This model has allowed the study of some aspects related
to tumour behaviour or possible treatment strategies in vivo
[69].
This model shows that after the exposure of pregnant
Sprague Dawley rats on the 15th day of gestation to a single
intraperitoneal injection of 80mg ENU/kg body weight,
more than half of the oﬀspring developed intracerebral
tumours, diagnosed as gliomas [17, 27]. According to
histopathological features, immunophenotyping, prolifera-
tion index for Ki-67, and MRI study, we have demonstrated
that this model reproduces quite closely the neuropathology
of oligodendrogliomas and glioblastoma [31, 70].
Three glioma development stages were identified: early
(microtumours), intermediate (the smallest macrotumours),
and advanced stages (corresponding to the largest macro-
tumours) (Figure 1). Microtumours corresponding with cell
proliferation mass and minor tumour node (Figure 1(a))
were diagnosed as low-degree gliomas, andmacrotumours as
anaplastic gliomas or high-degree gliomas (Figure 1(b)). The
largest macrotumours corresponded to highly infiltrative
malignant gliomas (Figure 1(c)). They displayed charac-
teristic features of glioblastomas, such as haemorrhages,
microvascular proliferation, macrocysts and necrosis with
pseudo-palisades [1, 17]. These results corroborate the origin
of secondary GBM from oligodendrogliomas, and not only
from astrocytoma cells.
ENU-tumour development shows that malignancy
degree is related to rat age and consequently to the glioma
size. In a fashion similar to human glioma pathology, the
neoplasm has to reach a symptomatic size. At the age of
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Figure 1: Brain coronal sections of Sprague Dawley rats exposed prenatally to ethylnitrosourea. Two columns show MRI on T1-w and T2-
w after gadolinium administration and the left column shows the necropsy thirty minutes after Evans Blue i.v. injection (a, b) or Indian
ink (c). (a) On T2-weighted images, tumours in the early development stage show a diminutive proliferation mass growing in association
with the subcortical white matter. The blood brain barrier (BBB) remains still intact, shown by the lack of contrast or dye extravasation
(microtumours). (b) Multiple tumours on the intermediate development stage. There is a BBB dysfunction indicated by extravasation of
Evans Blue and by gadolinium enhancing the contrast on T1 images (macrotumours). (c) A macrotumour in the advanced stage growing
over a whole hemisphere. It displays a heterogeneous signal on T2 and on T1 due to the presence of histopathological features of malignancy
such as haemorrhages, cysts, and necrosis. With Indian ink, brains show in black a ring of aberrant vessels surrounding the neoplasia. The
same typical shape of glioblastoma multiforme may be observed on MRI in T1 with gadolinium.
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Figure 2: Confocal microphotographs of the microvascular network during development of an ENU-induced glioma. Histochemistry for
tomato lectin (LEA-FITC) performed on 40 μm sections. (a) Similar angioarchitecture to the normal brain during the early stage. (b)
Tortuous and dilated vessels during the intermediate development stage. (c) The microvascular network is mainly composed of glomeruloid
vessels in the periphery area, (d) Occasional huge dilated vessels in the intratumour region (bar scale of 20 μm).
four months, proliferations of oligodendrocytes in the sub-
cortical whitematter are frequently seen. These proliferations
become nodular at six months, although the rats did not
display symptoms. These nodes grow and in one year may
occupy a half hemisphere, or extend even more toward the
contralateral hemisphere. These macrotumours may display
clinical signs, depending on size and malignancy.
Small tumours, characteristic of the early phase, remain
asymptomatic and undetected due to their small size, there-
fore, they are named microtumours. Several authors have
considered these noninvasive tumours as dormant tumours.
The existence of dormant tumours has notable implications
for the early detection and treatment of cancer [71].
6. Glioma Hypoxic Microenvironment
In primary tumours, the dormancy state is best defined as the
time between carcinogenic transformation and the onset of
inexorable progressive growth. There are several mechanisms
related to the emergence from tumour latency, and one of
them is the induction of angiogenesis. The escape of tumours
from dormancy depends on the cell population undergoing
an angiogenic switch that induces the neoformation of
functional vessels [72].
Prior to angiogenesis and to the acquisition of the
tumour stem cell phenotype, events like microvascular aber-
ration and subsequent intratumour hypoxia take place. The
tumour microvascular network suﬀers some adaptations
to the current requirements of the tumour. The ENU-
model allows microvascular changes to be followed before
angiogenesis. The adaptive changes of the microvasculature
from nonangiogenic gliomas (microtumours) to angiogenic
gliomas (macrotumours) involve an increase in the tumour
area occupied by the vascular network and a decrease in
vascular density [73]. We have demonstrated a transition
from the homogeneous capillary network of early stages to an
anarchic angioarchitecture in advanced stages (Figure 2). It
was found that the vessel density decreased and the vascular
size increased with increased malignancy [70]. ENU-gliomas
in the initial stage show microvessels very similar to normal
brain capillaries (Figure 2(a)), in the intermediate stage they
are already tortuous, disorganized, and dilated (Figure 2(b)),
and in the advanced stage they become anarchic and aberrant
with topographies such as multilayered “glomeruloid tufts”,
“garlands” of proliferated vessels (Figure 2(c)) and huge
dilated vessels (Figure 2(d)) [70].
Microvascular adaptations in early development stages
were based on vasodilatation, endothelium elongation, and
permeability increase mediated by VEGF without BBB dys-
function [70]. In malignant gliomas the microvascular adap-
tations vary according to blood flow perfusion. Permeability
increase in intratumour vessels is not enough to supply
the metabolic demand, and triggering of the angiogenesis
process on the tumour border is necessary.



































Figure 3: Expression of stem cell markers: CD133 (red) and Nestin (green), proangiogenic factor VEGF165 (red) and microvasculature
markers: LEA lectin (green) and GluT-1 (red) during the ENU-glioma development. (a–f) MRI on T2-w and T1-w after gadolinium
injection. (a, d) During the initial stage, the ENU-glioma grows in association with the subcortical white matter. It shows a homogeneous
hyperintense signal on T2-w (a) and an isointense signal on T1-w (d). (b) ENU-intermediate stage corresponds with the “angiogenic switch.”
(c, f) ENU-Glioblastoma displays heterogeneous hyperintense signal on T2 and on T1-w. (g-h) Overexpression of VEGF165 is shown in the
intermediate (h) and advanced stages. (i) Also shown in perivascular cells of glomeruloid vessels. (j–l) CD133 expression is found following
the intermediate stage (k). (l) ENU-GBM displays plenty of CD133+ cells in the intratumour hypoxic area and bordering the tumour. (m–o)
Nestin+ cells are detected in every ENU development stage. Nestin+ cells are grouped into intratumour niches and around the microvessels.
(Immunofluorescence images at 100x amplification, except I, l, and o at 40x).




Figure 4: Intermediate ENU glioma stage showing the expression of Nestin (green) and CD133 (red) by double immunofluorescence.
(a–c) Intratumour niches of glioma stem cells positive for Nestin (a) and CD133 (b). (c) Both stem cell markers, Nestin and CD133 are
coexpressed in some of these cells. (d–f) Isolated cells in the border of the tumour with a shape similar to astrocytes. Although the majority
of these cells are Nestin-CD133 positive, there is a greater density of Nestin+ cells than CD133+ ones. (g–i) Perivascular niche of glioma
stem cells displaying colocation of both markers.
7. The Angiogenic Switch
The transition from a prevascular proliferative node to a
highly vascularised and progressively outgrowing tumour is
referred to as the “angiogenic switch” [74]. Angiogenesis
is activated in growing gliomas when the proangiogenic
stimuli outweigh the antiangiogenic stimuli. This moment is
detected in the ENU-glioma intermediate stage by the pres-
ence of overexpression of VEGF and eNOS [75] (Figure 3).
In this phase, hypoxia increases VEGF and eNOS expression
through the activation of the PI-K/Akt cascade [76, 77].
In this intermediate stage, we identified glioma stem cells
by CD133 and Nestin immunostaining (Figure 4). We found
that some cells coexpress the Nestin, CD133 and VEGF165
antibodies. These cells were distributed in intratumour
niches and perivascular niches around the tortuous and aber-
rant vessels (intermediate-advanced stages). The distribution
of CD133+ cells corresponded mainly to overexpression
of VEGF in neoangiogenic border areas and intratumour
hypoxic areas of neoplasia [17, 70, 78]. It has been reported
that tumour stem cells over-express VEGF, so this cell
population could be involved in the process of angiogenesis.
Our results agree with the staining of CD133 described in
the advanced and intermediate stages of human gliomas.
Therefore, CD133 expression has been related to poor
prognosis [79].
In the ENU model, as in human GBMs, the angiogenic
factor VEGF-A and HIF-1α have been immunohistochem-
ically identified in cells located inside the pseudopalisade
area around necrosis. This feature provides a link between
hypoxia and angiogenesis in malignant gliomas [13, 39]
(unpublished data). In addition, we found Nestin+ and
CD133+ cells around necrotic areas as well [78]. These find-
ings support the idea that intratumour hypoxia contributes
significantly to the selection of glioma stem cells (GSCs) and
furthermore these groups of cells could be responsible for the
infiltrative process and neoplastic recurrences [9, 56].
8. Neovasculature and Tumour Invasiveness
Tumour microvasculature generates specific microenviron-
ments that promote the formation and/or maintenance of
brain GSCs. New vessels often show immature walls that
are inherently leaky. Tissue may become oedematous. In
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previous studies, the neoangiogenic area of these tumours
was replete with small vessels overexpressing VEGF and
displaying an irregular staining for BBB markers [70]. It
is a fact that, even though brain tumour vessels appear
more “leaky” than their normal tissue counterpart, at least
some elements of the BBB in glioblastoma remain intact.
Permeability is varied, and the heterogeneity of permeability
contributes to uneven distribution of transport products,
such us oxygen and chemotherapeutic drugs within the
tumour [80].
It has also been proposed that the abnormal blood vessels
in gliomas create a vascular niche that houses glioma stem
cells [81, 82]. This “perivascular niche” consists of a rich
extracellular matrix (ECM) and nontumoural cells, which
provide a physical support for tissue architecture. There is
consistent evidence about the migration of GSCs using the
ECM [83, 84]. If the recruitment of aberrant vascular niches
is a critical component in the progression of brain tumours,
this might explain why the most aggressive brain tumours
are highly angiogenic [19, 85]. Moreover, VEGF isoforms are
at least partially bound to the ECM, and their degradation
could provide an extra source of growth factors [86].
Calabrese and colleagues [81] showed that endothelial
cells (ECs) interact closely with brain tumour stem cells in
the perivascular location (termed the perivascular niche) and
secrete factors that maintain these cells in a stem cell-like
state. Moreover, recent studies of orthotopic glioblastoma
xenografts suggested that GSCs of these brain tumours
secrete angiogenic factors that promote the recruitment and
formation of tumour blood vessels [24].
Folkins and colleagues [60] compared the angiogenesis
in tumour xenografts from C6 glioma cells containing either
a low or a high fraction of GSCs and found that GSC-high
xenograft tumours demonstrated an increased microvessel
density and blood perfusion.
9. Conclusion
Glioma survival and growth is dependant on angiogen-
esis. Angiogenesis is a complex process in which several
cellular and molecular pathways are involved. Among the
cellular pathways, glioma stem cells and vascular endothe-
lial cells play a relevant role, and among the molecular
pathways, hypoxia inducible factor -1 (HIF-1) and vascular
endothelial growth factor (VEGF) are the most significant.
Both molecular mediators are related to glioma stem cells.
Therefore, hypoxia selects the GSCs that induce the start of
the angiogenesis process by the synthesis of proangiogenic
factors such a angiopoietin, ECM factors and VEGF, and
decrease angiostatic factors [87]. On the other hand, GSCs
mediate vascular adaptation not only by the synthesis of
vascular permeability factors or angiogenic factors, but also
by diﬀerentiation in endothelial cells of the neovascular
network.
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